CORDIS
EU research results

CORDIS

English EN

Novel precision technological platforms to promote non-invasive early diagnosis, eradication and prevention of cancer relapse: proof of concept in the bladder carcinoma.

Objective

Unmet clinical needs in the management of bladder cancer (BCa) are the prevention of tumor onset, relapse and progression, and therapy of the aggressive carcinoma in situ (Cis), requiring weekly treatments and endless follow-up, with a consequent poor quality of life and the highest cost per patient among all cancers. Therefore, public health programs crave for early BCa detection protocols, to improve performance in the management of this devastating disease. Here we propose an advanced transformative technology termed EDIT combining a novel high-resolution ultrasound elastography and photoacoustic imaging on the bladder instilled with targeted plasmonic gold sensors.
EDIT approach exploits the structural and mechanical properties of the bladder extracellular matrix (ECM) as a unique biomarker of the early onset/progression/relapse of carcinoma, through engineered novel gold nanorods (GNRs) used as intravesical photoacoustic antennas targeted at the ECM, generating an ad hoc visualization platform. GNRs will be further utilized as heat-releasing effectors at nanoscale for targeted cancer photo-thermal therapy. EDIT is designed to detect pre-neoplastic area and eradication of local areas at few cells resolution with high sensitivity and specificity.
We bring together a multi and transdisciplinary consortium capable to develop non-invasive and non-ionizing novel technology and preclinical validation for early prognosis of BCa and therapeutic nanomedicine against bladder Cis. Outcomes of EDIT will revolutionize the management of BCa with the introduction of sensing and effector nanotechnologies combined with non-invasive organ imaging with high resolution/definition by 3D ultrasound and photoacoustic imaging.
Structural and mechanical modification of the ECM is a common denominator for invasive breast, colorectal, prostate and bladder cancers. EDIT platforms will also pave the ways for the earlier management of other bladder-related pathologies and solid tumors.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

OSPEDALE SAN RAFFAELE SRL

Address

Via Olgettina 60
20132 Milano

Italy

Activity type

Private for-profit entities (excluding Higher or Secondary Education Establishments)

EU Contribution

€ 1 146 963,75

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

UNIVERSITA DEGLI STUDI DI MILANO

Italy

EU Contribution

€ 480 125

ALMA MATER STUDIORUM - UNIVERSITA DI BOLOGNA

Italy

EU Contribution

€ 374 350

FUJIFILM SONOSITE BV

Netherlands

EU Contribution

€ 681 625

WEIZMANN INSTITUTE OF SCIENCE

Israel

EU Contribution

€ 350 225

LIME TECHNOLOGY IKE

Greece

EU Contribution

€ 298 570

ASCEND TECHNOLOGIES LIMITED

United Kingdom

EU Contribution

€ 400 500

OSM-DAN LTD

Israel

EU Contribution

€ 216 363,75

CONSIGLIO NAZIONALE DELLE RICERCHE

Italy

EU Contribution

€ 368 437,50

Project information

Grant agreement ID: 801126

Status

Ongoing project

  • Start date

    1 October 2018

  • End date

    30 September 2022

Funded under:

H2020-EU.1.2.1.

  • Overall budget:

    € 4 317 160

  • EU contribution

    € 4 317 160

Coordinated by:

OSPEDALE SAN RAFFAELE SRL

Italy